Somatic alterations in the human cancer genome.

Most human malignancies are caused by somatic alterations within the cancer genome, leading to oncogene activation or tumor suppressor gene inactivation. The sequence of the human genome has enabled systematic approaches to identify cancer genome alterations, including point mutations, copy number increases and decreases, loss of allelic heterozygosity, and chromosome translocations. Systematic cancer genome analysis has recently led to the discovery of somatic mutations in the BRAF, PIK3CA, and EGFR genes, among others. With further development of targeted cancer therapies and improvement in genome analysis technology, genome-wide surveys of cancer will likely become tools for diagnosis as well as discovery.

[1]  R. Wilson,et al.  EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[2]  Jay Shendure,et al.  Fluorescent in situ sequencing on polymerase colonies. , 2003, Analytical biochemistry.

[3]  C R King,et al.  Amplification of a novel v-erbB-related gene in a human mammary carcinoma. , 1985, Science.

[4]  Paul Cairns,et al.  Genome-wide genetic characterization of bladder cancer: a comparison of high-density single-nucleotide polymorphism arrays and PCR-based microsatellite analysis. , 2003, Cancer research.

[5]  Carissa A. Sanchez,et al.  Comparative genomic analysis of tumors: detection of DNA losses and amplification. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[6]  D J Lockhart,et al.  Genome-wide detection of allelic imbalance using human SNPs and high-density DNA arrays. , 2000, Genome research.

[7]  W F Bodmer,et al.  The ABC of APC. , 2001, Human molecular genetics.

[8]  C. Nusbaum,et al.  Large-scale identification, mapping, and genotyping of single-nucleotide polymorphisms in the human genome. , 1998, Science.

[9]  William Pao,et al.  Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Y. Nakamura,et al.  Allelotype of colorectal carcinomas. , 1989, Science.

[11]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[12]  R. Lewontin,et al.  Mutation and cancer , 2000 .

[13]  Rithy K. Roth,et al.  Gene expression analysis by massively parallel signature sequencing (MPSS) on microbead arrays , 2000, Nature Biotechnology.

[14]  Rob Pieters,et al.  Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. , 2003, Cancer cell.

[15]  Thomas LaFramboise,et al.  Genomic representations using concatenates of Type IIB restriction endonuclease digestion fragments. , 2004, Nucleic acids research.

[16]  David C Christiani,et al.  High-resolution single-nucleotide polymorphism array and clustering analysis of loss of heterozygosity in human lung cancer cell lines , 2004, Oncogene.

[17]  J. V. Moran,et al.  Initial sequencing and analysis of the human genome. , 2001, Nature.

[18]  Chen-Yang Shen,et al.  PIK3CA as an oncogene in cervical cancer , 2000, Oncogene.

[19]  R. Weinberg,et al.  How cancer arises. , 1996, Scientific American.

[20]  J. Rowley.  A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa Staining , 1973, Nature.

[21]  Joe W. Gray,et al.  PIK3CA is implicated as an oncogene in ovarian cancer , 1999, Nature Genetics.

[22]  P. Dahia,et al.  PTEN, a unique tumor suppressor gene. , 2000, Endocrine-related cancer.

[23]  Stephen H. Friend,et al.  A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma , 1986, Nature.

[24]  Christian A. Rees,et al.  Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[25]  J. Ptak,et al.  High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.

[26]  J. Hoeijmakers.  Genome maintenance mechanisms for preventing cancer , 2001, Nature.

[27]  T. Hubbard,et al.  A census of human cancer genes , 2004, Nature Reviews Cancer.

[28]  F. Mitelman,et al.  Recurrent chromosome aberrations in cancer. , 2000, Mutation research.

[29]  K. Kinzler,et al.  Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. , 1995, Science.

[30]  K. Kinzler,et al.  Genetic instabilities in human cancers , 1998, Nature.

[31]  Meenhard Herlyn,et al.  BRAF as a potential therapeutic target in melanoma and other malignancies. , 2003, Cancer cell.

[32]  Daniel Pinkel,et al.  Genomic microarrays in human genetic disease and cancer. , 2003, Human molecular genetics.

[33]  S. Knuutila,et al.  DNA copy number amplifications in human neoplasms: review of comparative genomic hybridization studies. , 1998, The American journal of pathology.

[34]  M. Meyerson,et al.  Missense mutations of the BRAF gene in human lung adenocarcinoma. , 2002, Cancer research.

[35]  L. Chin,et al.  High-Resolution Global Profiling of Genomic Alterations with Long Oligonucleotide Microarray , 2004, Cancer Research.

[36]  G. Parmigiani,et al.  Mutational Analysis of the Tyrosine Kinome in Colorectal Cancers , 2003, Science.

[37]  Andrew D. Yates,et al.  Athletics: Momentous sprint at the 2156 Olympics? , 2004, Nature.

[38]  M. Shapero,et al.  High-resolution analysis of DNA copy number using oligonucleotide microarrays. , 2004, Genome research.

[39]  Scott E. Kern,et al.  DPC4, A Candidate Tumor Suppressor Gene at Human Chromosome 18q21.1 , 1996, Science.

[40]  Päivikki Kauraniemi,et al.  Amplification of a 280-kilobase core region at the ERBB2 locus leads to activation of two hypothetical proteins in breast cancer. , 2003, The American journal of pathology.

[41]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[42]  Bradley P. Coe,et al.  A tiling resolution DNA microarray with complete coverage of the human genome , 2004, Nature Genetics.

[43]  M. Skolnick,et al.  A cell cycle regulator potentially involved in genesis of many tumor types. , 1994, Science.

[44]  Giovanni Parmigiani,et al.  Mutational Analysis of the Tyrosine Phosphatome in Colorectal Cancers , 2004, Science.

[45]  T. Yamamoto,et al.  The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. , 1986, Science.

[46]  T. Rabbitts,et al.  Chromosomal translocations in human cancer , 1994, Nature.

[47]  Cori Bargmann,et al.  The neu oncogene encodes an epidermal growth factor receptor-related protein , 1986, Nature.

[48]  P. Seeburg,et al.  Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. , 1985, Science.

[49]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[50]  K Autio,et al.  DNA copy number losses in human neoplasms. , 1999, The American journal of pathology.

[51]  Timothy B. Stockwell,et al.  The Sequence of the Human Genome , 2001, Science.

[52]  A. Knudson,et al.  Chasing the cancer demon. , 2000, Annual review of genetics.

[53]  G. Daley,et al.  Implicating the bcr/abl gene in the pathogenesis of Philadelphia chromosome-positive human leukemia. , 1991, Advances in cancer research.

[54]  A. Knudson.  Mutation and cancer: statistical study of retinoblastoma. , 1971, Proceedings of the National Academy of Sciences of the United States of America.

[55]  J. Sebat,et al.  Representational oligonucleotide microarray analysis: a high-resolution method to detect genome copy number variation. , 2003, Genome research.

[56]  K. Kinzler,et al.  Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status , 2002, Nature.

[57]  Sridhar Ramaswamy,et al.  Loss of Heterozygosity and Its Correlation with Expression Profiles in Subclasses of Invasive Breast Cancers , 2004, Cancer Research.

[58]  Richard Wooster,et al.  BRAF and RAS mutations in human lung cancer and melanoma. , 2002, Cancer research.

[59]  J. Shendure,et al.  Advanced sequencing technologies: methods and goals , 2004, Nature Reviews Genetics.

[60]  Eric S. Lander,et al.  Loss-of-heterozygosity analysis of small-cell lung carcinomas using single-nucleotide polymorphism arrays , 2000, Nature Biotechnology.

[61]  High-resolution analysis of gene copy number alterations in human prostate cancer using CGH on cDNA microarrays: impact of copy number on gene expression. , 2004 .

[62]  P. Gergely,et al.  Lymphocyte surface immunoglobulins in Hodgkin's disease. , 1973, The New England journal of medicine.

[63]  Hiroyuki Konishi,et al.  The PIK3CA gene is mutated with high frequency in human breast cancers , 2004, Cancer biology & therapy.

[64]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[65]  Luc Girard,et al.  An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays. , 2004, Cancer research.

[66]  Jürg Zimmermann,et al.  Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells , 1996, Nature Medicine.

[67]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[68]  T. P. Dryja,et al.  Expression of recessive alleles by chromosomal mechanisms in retinoblastoma , 1983, Nature.

[69]  Michael R. Speicher,et al.  Digital karyotyping , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[70]  P. Nowell,et al.  Chromosome studies on normal and leukemic human leukocytes. , 1960, Journal of the National Cancer Institute.

[71]  B. Johansson,et al.  A breakpoint map of recurrent chromosomal rearrangements in human neoplasia , 1997, Nature Genetics.

[72]  D. Carson,et al.  Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers , 1994, Nature.

[73]  Cheng Li,et al.  Genome-wide loss of heterozygosity analysis from laser capture microdissected prostate cancer using single nucleotide polymorphic allele (SNP) arrays and a novel bioinformatics platform dChipSNP. , 2003, Cancer research.